Clinical Trials FAQ
Quick Questions And Answers About COVID-19 Clinical Trials.
Yes, those trials might become available.
Yes, but only to patients who previously participated in a vaccine clinical trial at this time.
Yes, those have already started to be administered.
Although none of the COVID-19 vaccines so far have shown untoward effects in pregnant women, all investigational products can have side effects. At this time, pregnant woman can only enroll in vaccine trials that are dedicated to them. Similarly, some conditions will prevent you from participating in a clinical trial (i.e. serious past allergic reactions, etc.).
Clinical trials help us understand how efficient vaccines are against the different COVID-19 variants; what dosage works best; how far apart boosters should be administered; whether different individuals respond differently; how long the protection lasts, etc. Participation helps us answer all those important questions so we can fight back against COVID-19. Participants are compensated for their time and travel and no medical insurance is needed.
The FDA has granted approval for some vaccines and treatments but with the periodic emergence of new variants, more trials are still needed looking at protection/efficiency against the new variants.
Yes, you are allowed to get a flu shot 14-28 days after your last study vaccine.
Participating in the study and receiving the vaccine will not cause you to get your family members to get sick. You will still need to follow State & Government guidelines to decrease the transmission of the virus as you normally would.
The simple answer is Yes. Additional vaccines will be required to meet the global needs to combat the SARS CoV-2 virus (coronavirus) because no single vaccine is right for everyone, no single company can supply sufficient vaccine doses for global needs and differences among the vaccines lead to different needs with respect to storage, shelf-life, distribution requirements, etc.
Each vaccine needs to be evaluated to learn the level of protection from disease it provides – termed “absolute efficacy” -- which is determined by comparing the vaccine to no vaccine (or placebo). Only with this sort of information in hand can regulators and healthcare providers assess which vaccines work best for which people and how they should be used.
Yes, you can still participate in the vaccine study as long as the panel/questionnaire study you are participating in does not provide any type of COVID-19-related treatment.
People in a study are free to leave at any time as their participation is purely voluntary. We ask that people who choose to leave to get vaccinated with an approved vaccine continue to attend study appointments and share data on their health and any infection with COVID-19 for as long as possible, so that the study can complete as early as possible.
Learning whether you received a placebo or the drug (being unblinded) will not affect your medical care or follow-up in the study. Unblinding will remove you from the study population that will contribute to determining how well a vaccine works, which initially prompted your voluntary participation. Demonstrating the vaccine is effective and safe could become more difficult if people choose to unblind.
Depending on the study, some participants may receive a placebo, while others will receive the vaccine. Several study vaccines have shown to be very effective in protecting against COVID-19. Whether you receive the actual vaccine or a placebo, you should continue to follow CDC guidelines and practice social distancing.